DelveInsight’s, “Malignant Mesothelioma Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant Mesothelioma pipeline landscape. It covers the Malignant Mesothelioma pipeline drug profiles, including Malignant Mesothelioma clinical trials and nonclinical stage products. It also covers the Malignant Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Malignant Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Malignant Mesothelioma clinical trials studies, Malignant Mesothelioma NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from the Malignant Mesothelioma Pipeline Report

 

• Over 20+ Malignant Mesothelioma companies are evaluating 20+ Malignant Mesothelioma pipeline therapies in various stages of development, and their anticipated acceptance in the Malignant Mesothelioma market would significantly increase market revenue.

 

• The leading Malignant Mesothelioma Companies includes Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others.

 

• Promising Malignant Mesothelioma Pipeline Therapies includes Nivolumab, Ipilimumab, Pemetrexed, MTG201, Tremelimumab, ZD1839, THOR-707, Tazemetostat, Cisplatin, Anetumab ravtansine (BAY94-9343), Vinorelbine, NGR-hTNF, and others.

 

• The Malignant Mesothelioma companies and academics are working to assess challenges and seek opportunities that could influence in Malignant Mesothelioma R&D. The Malignant Mesothelioma pipeline therapies under development are focused on novel approaches to treat/improve in Malignant Mesothelioma.

 

To explore more information on the latest breakthroughs in the Malignant Mesothelioma Pipeline treatment landscape of the report, click here @ Malignant Mesothelioma Pipeline Outlook

 

Malignant Mesothelioma Overview

Malignant mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Mesothelial cells form the lining layers of the viscera. Mesothelioma can occur at any mesothelial layer such as the peritoneum or pericardium. The pleural layer is by far the most commonly affected, giving rise to malignant pleural mesothelioma. The risk of developing mesothelioma was described as 10% over the lifetime of an asbestos worker, with up to 70% of all mesothelioma cases involving documented asbestos exposure.

 

Latest News or Breakthroughs of the Malignant Mesothelioma Treatment Landscape

 

• In April 2022, Ascentage Pharma announced that the combination of palbociclib and APG-2449 synergistically inhibits tumor growth in mesothelioma and such effect is mediated by induced autophagy and enhanced cellular senescence. The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development.

 

• In July 2021, The FDA granted an orphan drug designation to the anticancer drug paclitaxel-hyaluronic acid (Oncofid-P) for the treatment of malignant mesothelioma, according to a press release by Fida Farmaceutici.

 

For further information, refer to the detailed Malignant Mesothelioma Unmet Needs, Malignant Mesothelioma Market Drivers, and Malignant Mesothelioma Market Barriers, click here for Malignant Mesothelioma Ongoing Clinical Trial Analysis

 

Malignant Mesothelioma Emerging Drugs Profile

 

INCB001158: Incyte Corporation

INCB001158 (CB-1158) is an investigational first-in-class, novel small molecule arginase inhibitor. Arginase is an enzyme that suppresses the immune-mediated destruction of tumors by depleting levels of a key amino acid, L-arginine, from the tumor microenvironment. A number of cell types in the tumor microenvironment, including myeloid-derived suppressor cells, macrophages, and neutrophils, can secrete arginase. L-arginine deprivation can act via nutrient sensor pathways to exert several suppressive effects on T-cell function, inhibiting proliferation, decreasing cytokine production, and diminishing expression of the T-cell receptor CD3ζ chain. Arginase activity may thus impair T-cell mediated anti-tumor responses

 

RSO-021: RS Oncology

RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage.

 

Pegargiminase: Polaris Pharmaceuticals

Pegargiminase (ADI-PEG 20) is a potential first-in-class targeted cancer therapy in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma (HCC) and malignant pleural mesothelioma (MPM). Pegargiminase is well tolerated, both as a monotherapy and as part of a combination therapy.

 

Malignant Mesothelioma Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Malignant Mesothelioma. The companies which have their Malignant Mesothelioma drug candidates in the most advanced stage, i.e. Phase III include, Polaris Pharmaceuticals.

 

Request a sample and discover the recent advances in Malignant Mesothelioma Ongoing Clinical Trial Analysis and Medications, click here @ Malignant Mesothelioma Treatment Landscape

 

Scope of the Malignant Mesothelioma Pipeline Report

• Coverage- Global
• Malignant Mesothelioma Companies- Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others.
• Malignant Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, Tremelimumab, ZD1839, THOR-707, Tazemetostat, Cisplatin, Anetumab ravtansine (BAY94-9343), Vinorelbine, NGR-hTNF, and others.
• Malignant Mesothelioma Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for Malignant Mesothelioma Market Drivers and Malignant Mesothelioma Market Barriers, click here @ Malignant Mesothelioma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Malignant Mesothelioma Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malignant Mesothelioma  – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pegargiminase – Polaris Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Niraparib: Merck
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. YS110: Ys Therapeutics
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. IAG933: Novartis
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Malignant Mesothelioma  Key Companies
24. Malignant Mesothelioma  Key Products
25. Malignant Mesothelioma – Unmet Needs
26. Malignant Mesothelioma – Market Drivers and Barriers
27. Malignant Mesothelioma – Future Perspectives and Conclusion
28. Malignant Mesothelioma  Analyst Views
29. Malignant Mesothelioma  Key Companies
30. Appendix

 

Got Queries? Find out the related information on Malignant Mesothelioma Mergers and acquisitions, Malignant Mesothelioma Licensing Activities @ Malignant Mesothelioma Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services